Expanded colorectal cancer panel tests more genes

Mayo Clinic Laboratories has developed a new colorectal cancer panel in response to the latest recommendations for testing and treatment from the American Society of Clinical Oncology. The expanded MayoComplete Colorectal Cancer Panel (Mayo ID: MCCRC) uses next-generation sequencing and is suitable both for patients with cancer confined to the colon and for cases of metastatic colorectal cancer.

In addition to covering multiple gene mutations, MCCRC assesses for microsatellite instability and Lynch syndrome. Microsatellite instability is a key biomarker for response to checkpoint inhibitor treatment. The American Society of Clinical Oncology recommends that all people diagnosed with colorectal cancer be tested for Lynch syndrome, which is an inherited cancer syndrome.

To learn more, check out this test-specific episode of the “Answers From the Lab” podcast on Mayo Clinic Laboratories Insights.

Kevin Ritchart

Kevin Ritchart is a copywriter at Mayo Clinic Laboratories. He joined the company in 2022 and has nearly 10 years of experience writing for healthcare and scientific audiences.